Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HD204 versus Avastin in metastatic or recurrent non-squamous non-small cell lung cancer
2017-005175-78Phase 3Completed
- Sponsor
- Prestige Biopharma Limited
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of HLX04, bevacizumab in Non-small cell lung cancer (NS-NSCLC), sponsored by Prestige Biopharma Limited. Started May 2019; status: completed.
02
Drugs
HLX04bevacizumab
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on 2017-005175-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005175-78.